Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 3067-3068

  Mehta, Rita S ^a   Jackson, Donna ^a   Schubbert, Toni ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; STEROID RECEPTOR;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; BREAST TUMOR; DRUG ADMINISTRATION; FEMALE; NOTE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PACLITAXEL; RECEPTORS, STEROID;

EID: 67649995780     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.9377     Document Type: Letter

References (9)

1. Hugh J, Hanson J, Cheang MC, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176
2. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
3. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
4. Mehta RS: Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: A step toward reversing triple-negative paradox. J Clin Oncol 26:3286-3288, 2008; author reply 3288
5. Mehta RS: Hormone receptor, grade, human epidermal growth factor receptor 2, and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:2596, 2008; author reply 2596-2597
6. Mehta R: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197-198, 2008; author reply 198
7. Mehta RS, Hsiang D, Lane K, et al: Association between pathologic complete response and survival in patients treated with sequential anthracyclines and concomitant taxanes and trastuzumab in HER2-positive breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 3141)
8. Womer RB, West DC, Krailo MD, et al: Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 26:554s, 2008 (suppl; abstr 10504)
9. Isonishi S, Yasuda M, Takahashi F, et al: Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 26:294s, 2008 (suppl; abstr 5506)